Home - SelectION, Inc.

Klinische Studie – Atopische Dermatitis (Clinical Trial – Germany)

Zur Studie

with superior selectivity and specificity

Therapeutic peptides

toxins of venomous animals

Derived from evolutionary tuned

which selectively

Peptide drugs

target ion channels

for autoimmune patients

Improving quality of life

Targeting Ion Channels

MORE

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News

Meet selectION, Inc. at the BIO-Europe in Munich, on November 6^th to 8^th, 2023

September 25, 2023

SAN DIEGO, Sept 25, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the Phase 1b clinical trial in autoimmune disease.

BioWorld: Selection waits on efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis

June 2, 2023

By Cormac Sheridan, Staff Writer – Published by BioWorld™ – The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a target in autoimmune disease that has evaded the best efforts…

Klinische Studie – Atopische Dermatitis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

Meet selectION, Inc. at the BIO-Europe in Munich, on November 6^th to 8^th, 2023

BioWorld: Selection waits on efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis

About

Recent News

Contact

Klinische Studie – Atopische Dermatitis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

Meet selectION, Inc. at the BIO-Europe in Munich, on November 6th to 8th, 2023

BioWorld: Selection waits on efficacy data from trial of Kv1.3 ion channel blocker in atopic dermatitis

About

Recent News

Contact

Meet selectION, Inc. at the BIO-Europe in Munich, on November 6^th to 8^th, 2023